Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

MC2 Therapeutics, corporate

MC2 Therapeutics,

17.02.2021 - 09:04:44

MC2 Therapeutics: Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora Cream for treatment of Plaque Psoriasis

(+34) 659 614 173

Investors Relations Pablo Divasson del Frailepablo.divasson@almirall.com (+34) 93 291 30 87

MC2 Therapeutics Corporate Communications, Media and Investors Susanne Andersen Fitchsaf@mc2therapeutics.com (+45) 3131 5119

References:

1. Clinical trial IDs: NCT03802344 and NCT03308799 on Clinicaltrials.gov 2. IQVIA MIDAS(R) 3. Chandran, V., and S.P. Raychaudhuri. 2010. 'Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis', J. Autoimmune, 34: J314-J21 4. Schafer, T. 2006. 'Epidemiology of psoriasis. Review and the German perspective', Dermatology, 212: 327-37 5. WHO Global report on Psoriasis 2016

17.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

1168873??17.02.2021?

@ dgap.de